HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Michael S. Sweeney Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sweeney, M. S. Search for Related Content PubMed PubMed Citation Articles by Sweeney, M. S.

Ann Thorac Surg 1999;68:761-763
© 1999 The Society of Thoracic Surgeons

---

Innovative Circulatory Support Systems

The Hemopump in 1997: a clinical, political, and marketing evolution

^a Division of Cardiovascular and Thoracic Surgery, The University of Texas, Houston Medical School, and Department of Cardiovascular Surgery, Texas Heart Institute, Houston, Texas, USA

Address reprint requests to Dr Sweeney, 6410 Fannin, Suite 410, Houston, TX 77030

Presented at the Fourth International Conference on Circulatory Support Devices for Severe Cardiac Failure, Houston, TX, Oct 3–5, 1997.

Abstract

Background. The Hemopump (Medtronic, Inc, Minneapolis, MN) was conceived in 1975 and designed in 1982 as a temporary, extracorporeal cardiac assist system. Although it has been used clinically in Europe, it is not currently available in the United States.

Methods. In vitro and in vivo testing of the Hemopump began in 1983. Clinical investigations have included studies of patients in cardiogenic shock, Hemopump-supported coronary artery bypass operations in Sweden, and European studies of percutaneous transluminal coronary angioplasty (PTCA) with Hemopump support.

Results. The Hemopump has demonstrated positive hemodynamic effects in patients. Laboratory and clinical studies have shown that the nonpulsatile axial flow generates flows of up to 4.5 L/min while maintaining adequate perfusion of other organs. In Europe, hemopumps have been used successfully to support coronary bypass and PTCA.

Conclusions. The Hemopump system is simple, inexpensive, and well tolerated by the blood elements. Moreover, its design allows flexibility in supporting patients during cardiopulmonary bypass (in lieu of conventional techniques) and high risk angioplasty, as well as in rescuing patients with low cardiac output.

This article has been cited by other articles:

				D. Mancini and D. Burkhoff Mechanical Device-Based Methods of Managing and Treating Heart Failure Circulation, July 19, 2005; 112(3): 438 - 448. [Abstract] [Full Text] [PDF]

				T. Schmidt, J. Siefker, S. Spiliopoulos, and O. Dapunt New experience with the paracardial right ventricular axial flow micropump impella elect 600 Eur. J. Cardiothorac. Surg., August 1, 2003; 24(2): 307 - 308. [Abstract] [Full Text] [PDF]